Cabozantinib plus nivolumab showed a 71% response rate in FH-dRCC, extending efficacy beyond non-clear cell RCC. The study ...

Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease. Although late-stage kidney cancer generated ...

Keytruda and Lenvima combination showed a 50.6% overall response rate and 82.3% disease control rate in advanced non-clear cell kidney cancer. The median progression-free survival was 17.9 months, ...

Clear cell renal cell carcinoma (ccRCC) is still a clinical challenge due to its high metastasis rate at diagnosis and therapy resistance. It accounts for about 75%-80% of RCC cases. The magnesium ...

(Reuters) - A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone ...

A majority of patients with non-locally treated brain metastases from kidney cancer remained free of metastatic progression for at least 6 months when treated with cabozantinib (Cabometyx), a small ...

JACKSONVILLE, Fla. — Black people in the United States are at the highest risk for cancer death. According to the Centers for Disease Control, African Americans have a lower overall 5-year cancer ...

A Medical University of South Carolina Hollings Cancer Center researcher is exploring new ways to improve treatment options for kidney cancer patients. With funding from a Department of Defense (DOD) ...